Arcellx, Inc. ACLX

Updated: 12 Sep 2026

NASDAQ | Biotech | Biotechnology and cell therapy

No signal published yet

We already track Arcellx and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Arcellx free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology and cell therapy
We're already tracking Arcellx, Inc. — here are the latest events we've registered

Recent News

  • On April 28, 2026, Gilead Sciences completed its acquisition of Arcellx in a transaction valued at approximately $7.8 billion. Following the completion of the merger, Arcellx became a wholly owned subsidiary of Gilead Sciences and its common stock was delisted from NASDAQ.

What Firelda Watch includes for Arcellx, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Arcellx, Inc. will be delivered in the same format.

Want to follow Arcellx, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Arcellx free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Arcellx, Inc. ACLX
Arcellx — follow and we'll monitor it
Follow Arcellx free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.